Top Therapeutics Startups in 2026

Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments.

Omada Health is a virtual-first, integrated care provider. We combine the latest clinical protocols with breakthrough behavior science to make it possible for people with chronic conditions to achieve long-term improvements in their health. Working with over 1,600 enterprise customers – including Fortune 500 and small- and medium-sized employers, health plans, and health systems – Omada delivers personalized interventions for diabetes prevention and weight management, diabetes, hypertension, musculoskeletal issues and behavioral health. Our virtual care programs are clinically supported and evidence-based, and the results have been published in multiple peer-reviewed journals. We build programs that employees don’t just try, but stick with – resulting in reduced healthcare costs that deliver long term changes in health behavior and increased ROI. We're especially proud of the clinical results we deliver and the way we leverage technology to amplify and extend the influence of our real human care teams - from health coaches to clinical specialists. Omada has enrolled more than half a million members across all 50 states. Our partners include major employers across the country, including Costco and Iron Mountain, as well as leading health plans, such as Cigna and Kaiser.

Our story started when our co-founders, whilst working as medical doctors, recognized that the holistic textbook version of medicine was not at all what was being provided for patients. The reality is that a stretched healthcare system fails to engage people in their medical care at the preventative stages. As a result, the $3 trillion currently spent on healthcare goes on to prevents only 10% of premature deaths. With digital therapeutics, we have the opportunity to prevent 40% of premature deaths that are caused by behavioral patterns. Quit Genius is a behavior change platform that combines digital coaching, personalized content, wearable technology and medication to help people overcome addictive behaviors.

As population continues to age, there is a growing demand for motor rehabilitation services. The problem is that the way we address this growth or rehabilitation services (physical therapy) has not changed in thirty years because we are still heavily reliant on a one-to-one patient therapist interaction which is costly, non scalable, and difficult to ensure consistent quality. At SWORD Health, we saw the opportunity to take a truly disruptive and transformative approach to this problem by creating the first digital therapy solution that addresses the growing demand for therapy while reducing costs, empowering patients with their recovery to ultimately recover faster, and providing a rich source of data for clinical teams and decision makers. Video: vimeo.com/118489111

Force works with surgeons and their Care Teams to seamlessly support their patient’s journey. This unique approach combines a clinical voice with accessible technology, interactive, video-based education and patient-provider communication built upon each organization’s existing workflow. Our digital tools are used by patients in the home, engaging them in a daily, personalized care plan that drives successful recovery. Real-time data and outcomes are actively collected as patients move through their care, providing surgeon teams unprecedented insights into progress and performance outside the hospital. Force’s high level of patient engagement and outcomes are the result of 5 years of continuous improvement in every type of care setting with tens of thousands of users.

Loyal is a consumer-focused dog longevity & genomics company. We help our furry friends live longer, healthier lives. Loyal was internally incubated by Celine Halioua while at The Longevity Fund. Celine was previously a Ph.D. candidate at Oxford in gene therapy economics and holds a BSc in Neuroscience.

Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier. Our core portfolio currently consists of programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease. We are committed to partnering with patients to discover and develop new, effective medicines for neurodegenerative diseases.

Ground Truth Labs uses machine learning and computer vision to unlock insights from tissue and multi-modal data. Our mission is to improve outcomes for every cancer patient with AI driven insights from digital pathology. We're a lively, fast-paced, and cooperative team. If you're keen on joining us in our mission to use AI to alleviate the global impact of cancer, we'd be delighted to hear from you. Explore opportunities here on Wellfound and at groundtruthlabs.com/careers --- Tissue morphology contains an enormous amount of signal that is not captured by today's methods. We see the biggest opportunity in histology and have developed a platform to support biotech and pharmaceutical partners in their therapy development through a richer, more insightful understanding of underlying biology and the effects of their therapies on patients. Our interdisciplinary team has an extensive track record in machine learning, medical image analysis, pathology, clinical oncology, medical devices, and biopharma services. We deploy our platform in a number of development projects with pharma and have established collaborations with leading academic centers in the UK, Europe, and the United States.

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology

At IndieBio, we are committed to building a future where biology is not only a field of study, but a technology that will help solve our world’s most challenging problems. We are part of SOSV, one of the world's top early-stage investors, and our three-month programs are designed to put founders side-by-side every day with technical experts as well as provide $500,000 in capital to ensure a fast start for world shaping ideas. Graduates of IndieBio benefit from the remarkable IndieBio community as well as well as ongoing SOSV investment through A, B and later rounds. We have locations in New York City and San Francisco. If you are driven to change the world around you, then stop waiting: APPLY NOW!